Brukinsa was evaluated globally 
in 2 trials in a range of patients

Study
206

A Phase 2, open-label, multicenter, single-arm trial in patients with previously treated MCL following at least 1 prior therapy.*1,2

Study
003

A Phase 1/2, open-label, multicenter, single-arm trial in patients with previously treated MCL following at least 1 prior therapy.*1,3

ORR was assessed by an IRC according to the 2014 Lugano classification for non-Hodgkin lymphoma.

Baseline patient
characteristics1,4
Study 206 (N=86) Study 003 (N=32)
Median age 60.5 years (range: 34-75) 70 years (range: 42-86)
Caucasian 0% 78%
Median time since
diagnosis
2.5 years 4.5 years
Median prior
anticancer regimens
2 (range: 1-4) 1 (range: 1-4)
Disease history
   Refractory MCL
   Extranodal disease
   Blastoid variant of MCL

52%
71%
14%

25%
78%
6%
Prior ASCT 4% 16%
Most common prior regimens
   CHOP-based
   Rituximab-based

91%
74%

59%
94%
MIPI score
   Low risk
   Intermediate risk
   High risk

58%
29%
13%

28%
41%
31%

*In Study BGB-3111-206 (Study 206), patients were enrolled in China. In Study BGB-3111-AU-003 (Study 003), patients were enrolled in Australia, New Zealand, Europe, Asia, and the US.

In Study 206, PET scans were required for response assessment. In Study 003, PET scans were not required for response assessment and the majority of patients were assessed by CT scan.


ASCT=autologous stem cell transplant; CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone; CT=computed tomography; IRC=independent review committee; MCL=mantle cell lymphoma; MIPI=mantle cell lymphoma international prognostic index; ORR=overall response rate; PET=positron emission tomography.

Powerful And
Sustained Responses

Efficacy

Demonstrated
Safety Profile

Safety
myBeiGene

Personalized Patient
Support Program

Patient Support